請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/10314
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 高嘉宏(Jia-Horng Kao) | |
dc.contributor.author | Ching-Sheng Hsu | en |
dc.contributor.author | 許景盛 | zh_TW |
dc.date.accessioned | 2021-05-20T21:19:36Z | - |
dc.date.available | 2011-03-03 | |
dc.date.available | 2021-05-20T21:19:36Z | - |
dc.date.copyright | 2011-03-03 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-12-24 | |
dc.identifier.citation | 1. Seeff LB. Natural history of chronic hepatitis C. Hepatology. Nov 2002;36(5 Suppl 1):S35-46.
2. Chen DS. Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp. 1995;25:27-32. 3. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology. Nov 2002;36(5 Suppl 1):S3-20. 4. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. Dec 2003;362(9401):2095-2100. 5. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. Dec 1992;327(27):1899-1905. 6. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. Aug 1999;341(8):556-562. 7. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology. Jul 2000;32(1):91-96. 8. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. The New England journal of medicine. Apr 1999;340(16):1228-1233. 9. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med. Sep 1999;341(12):866-870. 10. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. Jun 1995;332(22):1463-1466. 11. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. Jun 1996;23(6):1334-1340. 12. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. Oct 1999;30(4):1054-1058. 13. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. Mar 1997;349(9055):825-832. 14. Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. May 1998;27(5):1435-1440. 15. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. Dec 1998;28(6):1687-1695. 16. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. Apr 2009;49(4):1335-1374. 17. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. Sep 2001;358(9286):958-965. 18. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. Sep 2002;347(13):975-982. 19. Kobayashi S, Takeda T, Enomoto M, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int. Mar 2007;27(2):186-191. 20. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. Mar 2004;140(5):346-355. 21. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis. 2003;23 Suppl 1:23-28. 22. Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther. Nov 2004;20(9):931-938. 23. Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology. Dec 2007;46(6):1732-1740. 24. Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol. May 2008;103(5):1131-1135. 25. Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology. Aug 1997;113(2):558-566. 26. Zeuzem S, Lee JH, Franke A, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology. Apr 1998;27(4):1149-1156. 27. Chayama K, Tsubota A, Kobayashi M, et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology. Mar 1997;25(3):745-749. 28. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology. Mar 2003;37(3):600-609. 29. Missiha S, Heathcote J, Arenovich T, Khan K. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol. Oct 2007;102(10):2181-2188. 30. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. Sep 2003;38(3):639-644. 31. Akuta N, Suzuki F, Suzuki Y, et al. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis. J Med Virol. Apr 2005;75(4):550-558. 32. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. Apr 2004;39(4):1147-1171. 33. Lin R, Liddle C, Byth K, Farrell GC. Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C. J Viral Hepat. Mar 1996;3(2):85-96. 34. Hsu CS, Liu CH, Liu CJ, et al. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir Ther. 2009;14(1):45-54. 35. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. Mar 2005;128(3):636-641. 36. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. Sep 2003;38(3):645-652. 37. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol. Jun 2007;22(6):832-836. 38. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. May 2006;43(5):954-960. 39. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. Sep 2005;43(3):425-433. 40. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. Jul 2007;357(2):124-134. 41. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. Jan 1995;373(6510):123-126. 42. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. Jan 1995;373(6510):117-122. 43. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. May 1997;387(6629):188-191. 44. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. Oct 1998;282(5386):103-107. 45. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A. Apr 1996;93(9):4398-4402. 46. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology. Jun 1999;29(6):1863-1869. 47. Perelson AS, Herrmann E, Micol F, Zeuzem S. New kinetic models for the hepatitis C virus. Hepatology. Oct 2005;42(4):749-754. 48. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology. Feb 1996;23(2):366-371. 49. Herrmann E, Neumann AU, Schmidt JM, Zeuzem S. Hepatitis C virus kinetics. Antivir Ther. Jun 2000;5(2):85-90. 50. Layden JE, Layden TJ. Viral kinetics of hepatitis C: new insights and remaining limitations. Hepatology. Apr 2002;35(4):967-970. 51. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. Jun 2003;37(6):1351-1358. 52. Shudo E, Ribeiro RM, Perelson AS. Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon alpha-2b. J Viral Hepat. May 2008;15(5):379-382. 53. Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology. Apr 2002;35(4):930-936. 54. Thiebaut R, Guedj J, Jacqmin-Gadda H, et al. Estimation of dynamical model parameters taking into account undetectable marker values. BMC Med Res Methodol. 2006;6:38. 55. Zung WW. A Self-Rating Depression Scale. Arch Gen Psychiatry. Jan 1965;12:63-70. 56. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. Apr 1979;134:382-389. 57. Pradat P, Tillmann HL, Sauleda S, et al. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat. Aug 2007;14(8):556-563. 58. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. Nov 2007;147(10):677-684. 59. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. Nov 2005;42(5):1208-1236. 60. Milazzo L, Meroni L, Galazzi M, et al. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. J Viral Hepat. Jul 2009;16(7):479-484. 61. Romero-Gomez M, Diago M, Andrade RJ, et al. Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology. Dec 2009;50(6):1702-1708. 62. Khattab M, Emad M, Abdelaleem A, et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int. Mar;30(3):447-454. 63. Ratziu V, Saboury M, Poynard T. Worsening of steatosis and fibrosis progression. Gut. Sep 2003;52(9):1386-1387. 64. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology. Dec 2003;125(6):1695-1704. 65. Sud A, Hui JM, Farrell GC, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology. May 2004;39(5):1239-1247. 66. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. Jul 2001;121(1):91-100. 67. Schaffler A, Scholmerich J, Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. Jun 2005;2(6):273-280. 68. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. Apr 2005;365(9468):1415-1428. 69. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. Nov 2005;42(5):987-1000. 70. Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin resistance. Diabet Med. Jun 2005;22(6):674-682. 71. Knobler H, Schattner A. TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad. Qjm. Jan 2005;98(1):1-6. 72. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. Oct 2000;133(8):592-599. 73. Wilson C. Hepatitis C infection and type 2 diabetes in American-Indian women. Diabetes Care. Sep 2004;27(9):2116-2119. 74. Petit JM, Bour JB, Galland-Jos C, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. Aug 2001;35(2):279-283. 75. Lecube A, Hernandez C, Genesca J, Esteban JI, Jardi R, Simo R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care. May 2004;27(5):1171-1175. 76. Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ. Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III]. Diabetes Res Clin Pract. Mar 2007;75(3):320-326. 77. Harrison SA. Correlation between insulin resistance and hepatitis C viral load. Hepatology. May 2006;43(5):1168; author reply 1168-1169. 78. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. Feb 2004;126(2):586-597. 79. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. Mar 2004;126(3):840-848. 80. Svegliati-Baroni G, Ridolfi F, Di Sario A, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology. Jun 1999;29(6):1743-1751. 81. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. Oct 2001;34(4 Pt 1):738-744. 82. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol. Dec 2003;39(6):1049-1055. 83. Hickman IJ, Powell EE, Prins JB, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol. Dec 2003;39(6):1042-1048. 84. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol. Jul 2007;47(1):142-156. 85. Cancello R, Clement K. Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG. Oct 2006;113(10):1141-1147. 86. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. Dec 14 2006;444(7121):840-846. 87. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest. Jun 2002;32 Suppl 3:24-34. 88. Itoh Y, Okanoue T, Ohnishi N, et al. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. Am J Gastroenterol. May 1999;94(5):1332-1340. 89. Zylberberg H, Rimaniol AC, Pol S, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol. Feb 1999;30(2):185-191. 90. Paz K, Hemi R, LeRoith D, et al. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem. Nov 1997;272(47):29911-29918. 91. Valenti L, Pulixi E, Fracanzani AL, et al. TNFalpha genotype affects TNFalpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. J Hepatol. Dec 2005;43(6):944-950. 92. Cooney RN. Suppressors of cytokine signaling (SOCS): inhibitors of the JAK/STAT pathway. Shock. Feb 2002;17(2):83-90. 93. Rico-Bautista E, Flores-Morales A, Fernandez-Perez L. Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions. Cytokine Growth Factor Rev. Dec 2006;17(6):431-439. 94. Song MM, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem. Dec 25 1998;273(52):35056-35062. 95. Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut. Apr 2006;55(4):529-535. 96. Emanuelli B, Peraldi P, Filloux C, et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem. Dec 2001;276(51):47944-47949. 97. Persico M, Capasso M, Persico E, et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology. Oct 2007;46(4):1009-1015. 98. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology. Dec 2003;38(6):1384-1392. 99. Pazienza V, Clement S, Pugnale P, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology. May 2007;45(5):1164-1171. 100. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. Jul 2004;40(1):46-54. 101. Wang AY, Hickman IJ, Richards AA, Whitehead JP, Prins JB, Macdonald GA. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. Am J Gastroenterol. Dec 2005;100(12):2717-2723. 102. Petit JM, Minello A, Jooste V, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab. Apr 2005;90(4):2240-2243. 103. Durante-Mangoni E, Zampino R, Marrone A, et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther. Nov 2006;24(9):1349-1357. 104. Cua IH, Hui JM, Bandara P, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology. Jul 2007;46(1):66-73. 105. Zografos TA, Liaskos C, Rigopoulou EI, et al. Adiponectin: A New Independent Predictor of Liver Steatosis and Response to IFN-alpha Treatment in Chronic Hepatitis C. Am J Gastroenterol. Jan 11 2008. 106. Lo Iacono O, Venezia G, Petta S, et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther. May 15 2007;25(10):1181-1191. 107. Romero-Gomez M, Castellano-Megias VM, Grande L, et al. Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol. May 2003;98(5):1135-1141. 108. Crespo J, Rivero M, Fabrega E, et al. Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig Dis Sci. Jul 2002;47(7):1604-1610. 109. Piche T, Vandenbos F, Abakar-Mahamat A, et al. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat. Jan 2004;11(1):91-96. 110. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. Dec 1994;21(6):1135-1139. 111. Duong FH, Filipowicz M, Tripodi M, La Monica N, Heim MH. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology. Jan 2004;126(1):263-277. 112. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. Apr 18 2002;346(16):1221-1231. 113. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology. Jul 2005;42(1):5-13. 114. Angulo P. NAFLD, obesity, and bariatric surgery. Gastroenterology. May 2006;130(6):1848-1852. 115. Day CP. From fat to inflammation. Gastroenterology. Jan 2006;130(1):207-210. 116. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. Feb 2006;43(2 Suppl 1):S99-S112. 117. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol. Apr 2004;40(4):578-584. 118. Jan CF, Chen CJ, Chiu YH, et al. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10). Int J Obes (Lond). May 2006;30(5):794-799. 119. Younossi ZM, McCullough AJ, Ong JP, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol. Sep 2004;38(8):705-709. 120. Roskams T, Yang SQ, Koteish A, et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol. Oct 2003;163(4):1301-1311. 121. Sell S. Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology. Mar 2001;33(3):738-750. 122. Lewindon PJ, Pereira TN, Hoskins AC, et al. The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease. Am J Pathol. May 2002;160(5):1705-1715. 123. Ezure T, Sakamoto T, Tsuji H, et al. The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am J Pathol. May 2000;156(5):1627-1639. 124. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology. Apr 2005;41(4):809-818. 125. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. Jul 2002;51(1):89-94. 126. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. Mar 2004;53(3):413-419. 127. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. Jul 2003;38(1):75-85. 128. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. Mar 2004;40(3):484-490. 129. Lam NP, Pitrak D, Speralakis R, Lau AH, Wiley TE, Layden TJ. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci. Jan 1997;42(1):178-185. 130. Jacobson IM, Brown RS, Jr., McCone J, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology. Oct 2007;46(4):982-990. 131. Fried MW, Jensen DM, Rodriguez-Torres M, et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology. Oct 2008;48(4):1033-1043. 132. Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology. Aug 2007;46(2):371-379. 133. Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. Jul 2008;135(1):111-121. 134. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology. Nov 2004;127(5 Suppl 1):S97-103. 135. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology. Jul 2002;36(1):150-155. 136. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. Feb 2004;126(2):460-468. 137. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology. Jun 2006;43(6):1295-1302. 138. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. Jul 2002;123(1):134-140. 139. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. Jun 2002;35(6):1485-1493. 140. Ohata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer. Jun 2003;97(12):3036-3043. 141. Moriya K, Nakagawa K, Santa T, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res. Jun 2001;61(11):4365-4370. 142. Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology. Feb 2002;122(2):352-365. 143. Kato T, Miyamoto M, Date T, et al. Repeated hepatocyte injury promotes hepatic tumorigenesis in hepatitis C virus transgenic mice. Cancer Sci. Aug 2003;94(8):679-685. 144. Yang S, Koteish A, Lin H, et al. Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. Hepatology. Feb 2004;39(2):403-411. 145. Fausto N. Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease. Semin Liver Dis. 1999;19(3):243-252. 146. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. Oct 2009;461(7265):798-801. 147. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. Sep 2009;461(7262):399-401. 148. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. Oct 2009;41(10):1100-1104. 149. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. Oct 2009;41(10):1105-1109. 150. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. Aug 2006;131(2):470-477. 151. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. Jan 2003;4(1):69-77. 152. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. Jan 2003;4(1):63-68. 153. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. Dec 2006;131(6):1887-1898. 154. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol. Mar 2005;79(6):3851-3854. 155. Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol. Feb 2005;174(4):1932-1937. 156. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. Jun 1995;22(6):696-699. 157. Ohno O, Mizokami M, Wu RR, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. Jan 1997;35(1):201-207. 158. Okamoto K, Akuta N, Kumada H, Kobayashi M, Matsuo Y, Tazawa H. A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b. J Virol Methods. Apr 2007;141(1):1-6. 159. Kato N, Yoshida H, Ono-Nita SK, et al. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology. Aug 2000;32(2):405-412. 160. Nowak M, Swietochowska E, Marek B, et al. Changes in lipid metabolism in women with age-related macular degeneration. Clin Exp Med. Mar 2005;4(4):183-187. 161. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. Jul 1985;28(7):412-419. 162. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. Sep 2007;46(3):912-921. 163. Huang KC. Obesity and its related diseases in Taiwan. Obes Rev. Mar 2008;9 Suppl 1:32-34. 164. Harrison SA, Rossaro L, Hu KQ, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology. Sep;52(3):864-874. 165. Ramcharran D, Wahed AS, Conjeevaram HS, et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology. Sep;52(3):854-863. 166. Jarmay K, Karacsony G, Nagy A, Schaff Z. Changes in lipid metabolism in chronic hepatitis C. World J Gastroenterol. Nov 2005;11(41):6422-6428. 167. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology. Oct 2009;50(4):1030-1037. 168. Hsu CS, Liu CJ, Lai MY, Chen PJ, Kao JH, Chen DS. Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated inter | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/10314 | - |
dc.description.abstract | C型肝炎病毒感染一直是全球公共衛生上的重要課題。根據世界衛生組織的估計,全球目前至少有一億八千萬以上的人遭到C肝病毒的感染。就C肝病毒感染的自然史而言,急性C肝病毒感染後有百分之五十五到八十五的人會變成為慢性的C肝病毒感染。這些慢性C肝病毒感染者中有七成在10年後變成慢性C型肝炎的患者,變成慢性C型肝炎的患者中,有近兩成的人在20年後會產生肝硬化。在肝硬化的C肝患者中,每年有百分之一到四的風險產生肝癌,百分之四到五的風險肝臟衰竭。
慢性C肝病毒感染治療的主要目標為永久消滅病毒,也就是持續追蹤檢驗C肝患者時仍檢測不到血清C肝病毒的核醣核酸。臨床上稱這些人為達到持續病毒學反應(sustained virologic response, SVR),就是病毒學上的C肝治癒(cure)。然而C肝病毒感染治療的終極目標為希望使C肝患者的肝臟組織學及臨床的相關參數能夠進步,一方面能減緩肝臟組織纖維化的進展及肝硬化產生,另一方面則希望能夠防止肝臟衰竭與肝癌的發生。 目前臨床上已有許多C肝病程進展以及干擾素治療的預測因子可以評估患者未來的預後以及接受治療後的反應,這些因素主要分為兩大類,一類是與病毒相關的因子,另一類則是與宿主(host)相關的因子,利用這些預測因子吾人將可以給予病人個人化的C肝追蹤及治療。與病毒相關的預測因子中,除了治療前的C肝病毒量與病毒基因型外,評估C肝患者接受治療時的C肝病毒量變化為目前臨床上預測患者SVR的重要參考指標。值得注意的是,最近許多臨床及實驗室研究皆指出,C肝病毒感染與宿主的葡萄糖代謝、脂質代謝及肝臟脂肪變性有密切的關係存在,宿主的代謝特徵會影響C肝患者的抗病毒治療效果。因此清楚了解C肝病毒感染與宿主葡萄糖代謝及脂質代謝的關係已經成為現今全球肝病研究中的熱門課題。 因此吾人研究的主要目標為釐清C肝病毒感染對葡萄糖代謝與脂肪代謝的影響,並且探討脂肪變性、胰島素抗性、以及脂肪細胞激素與C肝病毒感染的關係。找尋影響C肝病態生理機轉的可能標的,進而改善未來C肝患者臨床預後與治療。 因此在臨床研究部分,吾人首先比較C肝患者及健康成人在血清中代謝特徵的差異性。吾人發現,C肝患者會較健康成年人有較高的血清高密度脂蛋白膽固醇(high-density lipoprotein-cholesterol, HDL)、脂締素(adiponectin)濃度、但是較低的總膽固醇、三酸甘油酯與低密度脂蛋白膽固醇(low-density lipoprotein-cholesterol, LDL)濃度值。進一步比較C肝患者血清中代謝特徵與抗病毒治療效果時亦發現,C肝患者接受干擾素相關治療時的早期病毒量下降程度與身體質量指標(BMI)以及血清中的HDL 濃度有關。此外吾人亦發現血清中的C肝病毒量與血清中胰島素及三酸甘油酯濃度間存有正比例的關係,並且血清中C肝病毒量與宿主脂肪代謝特徵的關係會隨著C肝病毒基因型的不同而不同。進一步的研究更發現,雖然宿主的代謝特徵會影響C肝患者肝臟組織的纖維化,然而這個影響作用也會因不同C肝病毒基因型的感染而產生不一樣的效果。 另一方面,幾個重要的研究團隊最近共同指出,與介白質28B(interleukin 28B, IL28B, 合成interferon-λ3)相關之單核苷酸多形性(single nucleotide polymorphism, SNP)和C肝患者接受干擾素抗病毒藥物的治療效果間存有強烈的關聯性。因此吾人進一步研究C肝患者血清脂肪代謝特徵與IL28B SNP的關係性。初步的研究發現,帶有IL28B SNP rs8099917 的TT 基因型患者除了會較GT基因型患者在接受標準長效型干擾素治療後有較高的SVR外,TT 基因型患者也較GT基因型患者在接受治療前有較低的血清中三酸甘油酯濃度。 實驗室研究方面,吾人利用能表現不同濃度C肝基因型第一型病毒核心蛋白(HCV core protein)的肝癌細胞株(Huh 7-based cell lines)來分析宿主脂肪與膽固醇合成途徑上重要基因的表現。研究發現,表現C肝基因型第一型病毒核心蛋白的細胞較控制組有較低的細胞內三酸甘油酯與膽固醇濃度。此外不同濃度的C肝病毒核心蛋白對於細胞內膽固醇與脂肪酸製造途徑上的基因表現可以產生不同的影響,表現C肝基因型第一型病毒核心蛋白的細胞較控制組細胞,在3-羥基-3-甲基戊二酸單醯輔酶A合成酶 (3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) synthase)、還原酶(HMG-CoA reductase)以及微粒体三酸甘油酯轉移蛋白(microsomal triglyceride transfer protein, MTTP) 的mRNA表現量上都相對降低,但是在法尼基轉移酶1 (farnesyl-diphosphate farnesyltransferase 1, FDFT1)與ATP citrate lyase mRNA的表現量上則相對增加。C肝病毒核心蛋白低表現量細胞中SREBP1c的mRNA表現量為增加,但是其表現量會隨著C肝病毒核心蛋白量增加而逐漸下降。另外,表現C肝病毒核心蛋白的細胞較控制組在SREBP2 mRNA的表現量上相對增加,但是其表現量也會隨著C肝病毒核心蛋白量的增加而下降。 結語 醫學進步已使現今慢性C型肝炎病毒的感染成為一種可以治療、甚至治癒的疾病。目前臨床上依據不同的預測因子,包括C肝病毒基因型、治療中的病毒動力學變化以及宿主不同的單核苷酸多形性,已經可以給予患者更有效率與更少副作用的個人化治療。然而臨床因子對於C肝患者的自然病史以及抗病毒治療的影響,特別是宿主代謝因子對C肝患者干擾素治療的影響,以及背後的病態生理機轉,仍有待吾人累積更多的研究資料加以闡明。如果未來能夠對於宿主代謝因子與C肝病毒間之作用關係更加了解,吾人相信這些知識將能應用於臨床上,改善未來C肝患者的藥物治療方式,使其變得更有效率、副作用也更加減少。 | zh_TW |
dc.description.abstract | Hepatitis C virus (HCV) is a major causative agent of chronic hepatitis, liver cirrhosis, end-stage liver disease and hepatocellular carcinoma worldwide. About 55% to 85% HCV infected people will become chronic hepatitis, 5% to 20% of them will turn to liver cirrhosis after duration of 20 to 25 years, 30 % of these cirrhotic patients will become end stage liver disease in 10 years, and once cirrhosis is established, the risk of hepatocellular carcinoma is approximately 1% to 5 % per year. In Taiwan, about 2–4% Taiwanese people are chronic carriers of HCV; hence, effective tackling this virus is an important issue in Taiwan.
The goal of treating chronic hepatitis C (CHC) patients is to eradicate the virus or, in a clinical term, to attain a sustained virological response (SVR, defined as undetectable serum HCV RNA level 24 weeks after treatment cessation). However, currently approved pegylated interferon (Peg-IFN) plus ribavirin (RBV) therapy has many unpleasant side effects and is only effective in a certain proportion of patients with HCV genotype 1 (GT1) infection, especially in Western countries. Therefore, identifying baseline and on-treatment factors predictive of SVR in CHC patients is important in terms of increasing efficacy, avoiding unnecessary side effects and saving medical costs. Several factors have been linked to the therapeutic response of CHC patients, including viral factors, host factors, metabolic factors, histological factors, the type of regimens, and the duration of infection. Among these factors, early viral kinetics following therapy has become increasingly recognized and widely used in both clinical trials and daily practice. On the other hand, there is increasing interest in the impact of chronic HCV infection on metabolic abnormalities, including glucose, lipid, cytokines, insulin resistance and adipokines. Insulin resistance and type 2 diabetes have inceased incidence in CHC patients than in other disease or chronic hepatitis B patients, and serum lipid profiles as well as hepatic steatosis are associated with HCV infection and may afftect the therapeutic response of CHC patients. Howevr, the interacions between HCV infection and host metabolism as well as the underlying mechanisms remained not fully clarified. To examine the influence of hepatitis C virus infection on adipokines, glucose and lipid metabolism, we examine the underlying mechanisms by which HCV affects host adipokines, glucose and lipid metabolism, and vice versa, from both clinical and molecular points of views. We found CHC patients had higher alanine aminotransferase (ALT) and high-density lipoprotein-cholesterol levels, but lower total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol levels than controls. By using multiple linear regression analyses for subjects with available adiponectin data, presence of HCV infection was independently associated with higher serum adiponectin. In addition, we found body mass index and genotype were related to viral load decline at day 2, and baseline viral load and HDL level were correlated with viral load decline between day 2 and day 28 in multivariate analysis. Genotype 2, lower baseline viral load and more substantial viral load decline at day 28 predicted a higher SVR. Recently, several groups have found that the genetic polymorphism near IL28B gene may predict the therapeutic response of CHC GT 1 infected patients receiving Peg-IFN plus RBV. Thus, it is important and will be informative to evaluate the association of genetic polymorphism near IL28B gene, SVR and metabolic profiles in CHC GT 1 infected patients. We found Taiwanese CHC patients with rs8099917 TT genotype have a better SVR and lower baseline serum TG level than subjects with GT gentype. In the in vitro studies, we found that cells expressing HCV core proteins had lower cellular triglyceride and total cholesterol levels than controls (P<0.05, ANOVA; P<0.05, Nonparametric test for trend). HCV GT1 core proteins might down-regulate mRNA expressions of 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) synthase, HMG-CoA reductase and microsomal triglyceride transfer protein, but up-regulate mRNA expressions of farnesyl-diphosphate farnesyltransferase 1and ATP citrate lyase. Although mRNA expression of SREBP1c was up-regulated under lower levels of HCV core proteins, its expression was down-regulated with increasing HCV core protein levels. The mRNA expression of SREBP2 was up-regulated by HCV core proteins, but down-regulated with the increasing HCV core protein levels. CONCLUSIONS: HCV is a curable disease, and the evaluation of HCV genotype, viral kinetic parameters as well as host gene SNPs before treatment has let individualized therapies for CHC patients become possible approaches. However, the interactions and underlying mechanisms of host factors and HCV infection, especially glucose and lipid metabolsim as well as their impacts on therapeutic resposes, remain not fully understood. Further experimental and clinical studies based on these lines of evidence are needed to clearly clarify underlying mechanisms and provide clinicians useful information to opitimize the mangement of chronic HCV infection. | en |
dc.description.provenance | Made available in DSpace on 2021-05-20T21:19:36Z (GMT). No. of bitstreams: 1 ntu-99-D94421001-1.pdf: 1576364 bytes, checksum: 3fbad621e5fd536e1c050db9144469ca (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 口試委員會審定書…………………………………………….. i
誌謝……………………………………………………………. ii 中文摘要………………………………………………………. viii 英文摘要……………………………………………………….. xii 壹、緒論…………………………………………………… 1 第一章 C肝病毒感染的自然病史以及臨床治療……………… 4 第一節 C型肝炎病毒感染的自然史…………………………… 4 第二節C肝患者的預後以及治療的目標……………….………… 5 第三節 慢性C型肝炎患者的標準治療方式……………………… 5 第四節 慢性C肝患者對干擾素相關治療反應的臨床預測指標… 7 第五節 干擾素相關治療後的病毒學反應評估指標…………… 8 第六節 C肝病毒動力學…………………………………………… 10 第七節 接受抗病毒藥物治療的適當對象……………………… 12 第八節 抗C肝病毒藥物治療的臨床評估………………………… 13 第二章 C肝病毒感染與宿主脂質及葡萄糖代謝的關係…………15 第一節、 宿主葡萄糖及脂質代謝與C肝病毒的密切關係……… 15 第二節、 C肝病毒感染與宿主葡萄糖代謝的關係……………… 15 2.1葡萄糖代謝與胰島素抗性的產生………………………… 15 2.2 糖尿病、胰島素抗性與C肝病毒感染……………………. 16 2.3 C肝病毒感染引起胰島素抗性與肝臟纖維化的可能原因 17 2.4 C肝病毒引起胰島素抗性的分子機轉………….…………. 18 第三節、C肝病毒感染與宿主脂質代謝的關係………….……. 23 3.1 肝臟脂肪變性……………………………………………… 23 3.2 脂肪性肝病與其他慢性肝臟疾病的交互作用………..… 24 3.3 肥胖導致之非酒精性脂肪肝病與胰島素抗性………….. 24 3.4肝臟脂肪變性、脂肪肝炎與肝臟纖維化………………… 26 3.5肝臟脂肪變性和慢性C肝患者肝臟纖維化進展………… 27 3.6脂肪代謝惡化C肝患者肝臟纖維化的可能機轉………… 29 3.7 肝臟脂肪變性減少的正面效應…………………………… 31 3.8 脂肪變性與抗病毒治療反應的關係……………………… 32 3.9 肥胖、肝臟脂肪變性與酒精性肝臟疾病………………… 32 3.10肝臟脂肪變性、肥胖與肝癌……………………………… 33 3.11肝臟脂肪變性與藥物性肝臟疾病………………………… 35 3.12肝臟脂肪變性與其他肝臟疾病…………………………… 35 第四節、宿主基因多形性變異與新型抗C肝病毒藥物………… 37 4.1 介白質28B基因多形性與C肝病毒感染的相關性……… 37 4.2 IL28B基因的角色……................ ........... 39 4.3 新型抗C肝病毒治療藥物………………………………… 40 第五節、研究的問題及其重要性…………………….......... 40 第六節、研究的假說與特定目的………………............. 41 貳、研究方法與材料………………....................... 43 一、葡萄糖代謝及脂肪代謝與C型肝炎病毒感染之相關性研究 43 1.1探討慢性C肝病毒感染與患者體內代謝特徵的關係性……… 43 1.2探討慢性C肝患者血清中病毒量與胰島素抗性的關係性….. 43 1.3探討慢性C肝患者血清中病毒量與宿主脂肪特徵的關係性… 44 1.4探討慢性C肝患者接受長效型干擾素合併雷巴威林治療後早期病毒動力學與各種臨床特徵的關係性……………………………. . 46 1.5探討不同C肝病毒基因型對患者代謝特徵與肝臟組織學關係的影響性………………………………………………………….….…… 47 二、 C肝病毒蛋白對葡萄糖及脂肪代謝訊息傳遞途徑的影響和機制.. 48 三、實驗材料及方法……………………………… 48 叁、結果…............................................ 54 一、葡萄糖代謝及脂肪代謝與C型肝炎病毒感染之相關性研究….54 1.1探討慢性C肝病毒感染與患者體內代謝特徵的關係性……... 54 1.2探討慢性C肝患者血清中病毒量與胰島素抗性的關係性….. 55 1.3探討慢性C肝患者血清中病毒量與宿主脂肪特徵的關係性… 56 1.4探討慢性C肝患者接受長效型干擾素合併雷巴威林治療後早期病毒動力學與各種臨床特徵的關係性………………………………... 58 1.5探討不同C肝病毒基因型對患者代謝特徵與肝臟組織學關係的影響性……………………………………………………………..……. 62 二、 C肝病毒蛋白對葡萄糖及脂肪代謝訊息傳遞途徑的影響和機制.. 64 肆、討論……………………………………………………… 65 伍、展望…………………………………………………………… 87 陸、論文英文簡述………………………………………………… 96 柒、參考文獻…………………………………………………………109 表1-32等……………………..………………………………. 148-184 圖1-15等………………………………………..……………. 185-205 附錄:列出個人在碩博士班修業期間所發表之相關論文清冊 206-209 | |
dc.language.iso | zh-TW | |
dc.title | 慢性C型肝炎患者胰島素抗性、代謝和脂肪激素狀態:
病例對照研究與致病機轉探討 | zh_TW |
dc.title | Insulin resistance, metabolic and adipokine profiles in
chronic hepatitis C patients: Case-control study and mechanistic exploration | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-1 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 楊偉勛(Wei-Shiung Yang) | |
dc.contributor.oralexamcommittee | 林憲宏(Hans Hsienhong Lin),余明隆(Ming-Lung Yu),張明富(Ming-Fu Chang) | |
dc.subject.keyword | 慢性C型肝炎,C型肝炎病毒,持續病毒學反應,胰島素抗性,代謝,脂肪激素,單核苷,酸多形性, | zh_TW |
dc.subject.keyword | hepatitis C virus,chronic hepatitis C,insuin resistance,lipid metabolism,adipokines,sustained virologic response,single nucleotide polymorphism, | en |
dc.relation.page | 209 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2010-12-24 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf | 1.54 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。